Project Grant R21AR080957
Award Date
9/24/24
Completion Date
8/31/26
Dollars Obligated
$379K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $332,957 to the University of Georgia Research Foundation, Inc. to support research on heparan sulfate co-polymerase function and defects in disease. The key research objectives are to: 1) test hypotheses regarding active site residues of the EXT1-EXT2 co-polymerase complex and their roles in substrate recognition and catalysis;...
This $589,255 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop small RNA targeting approaches, such as microRNA and siRNA, to advance treatments for heterotopic ossification (HO). HO is a condition involving pathologic bone formation in soft tissues that can occur following orthopedic surgeries or injuries. The award will fund the...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $359,879 to the University of North Carolina at Chapel Hill to conduct research on the genetic basis of hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The research aims to build upon previous genome-wide association studies to identify additional genetic risk...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will fund research to develop improved gene replacement and editing therapies for Duchenne muscular dystrophy (DMD). The total award amount is $671,240 and the project period runs from January 22, 2025 to December 31, 2029. The key research objectives are to: 1) Refine technologies for expressing...
This $313,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will fund research by Emory University to establish phosphorylated WNT5A produced by osteoclasts as a potential anabolic bone drug. The research aims to determine how osteoclast-derived phospho-WNT5A can enhance bone formation in vivo and elucidate the cellular and molecular mechanisms by...
This Project Grant award, valued at $359,133.00, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports the generation of new genetic tools to enable more targeted and specific analysis of tendon and musculoskeletal tissues in mice. The goal is to develop constitutive and inducible FLP alleles that can be used in combination with existing...
This $718,693 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a collaborative research project between Henry Ford Health and Michigan State University Health Sciences to conduct whole-genome sequencing analysis of Hidradenitis Suppurativa (HS). The key objectives are to: 1) Perform whole-genome sequencing analysis to identify...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to investigate the novel role of HOX-expressing interstitial cells in muscle growth, homeostasis, and regeneration. The $557,357 award, effective March 14, 2025 through February 28, 2030, will be used by the University of Wisconsin-Madison to interrogate the potential of...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $395,537 to Brigham & Women's Hospital Inc. to develop and validate CRISPR-based genome editing strategies to correct genetic mutations in the CLCN7 gene that cause osteopetrosis, a rare and debilitating skeletal disorder. The project aims to optimize genome editing techniques in...